CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- Open-market buys, last 90 days
- $38,094
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$38,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2013-12-02 | Polymeropoulos Mihael Hristos President and CEO | Grant or award · Employee Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2013-12-02 | Polymeropoulos Mihael Hristos President and CEO | Grant or award · Restricted Stock Unit | +50,000 | 50,000 | ||
| 2013-12-02 | Kelly James Patrick SVP, CFO, Sec & Treasurer | Grant or award · Employee Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2013-12-02 | Kelly James Patrick SVP, CFO, Sec & Treasurer | Grant or award · Restricted Stock Unit | +20,000 | 20,000 | ||
| 2013-12-02 | Baroldi Paolo SVP & Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2013-12-02 | Baroldi Paolo SVP & Chief Medical Officer | Grant or award · Restricted Stock Unit | +20,000 | 20,000 | ||
| 2013-11-21 | Repella Robert SVP & Chief Commercial Officer | Exercise or conversion | +23,040 | $5.90 | $136K | 44,530 |
| 2013-11-21 | Repella Robert SVP & Chief Commercial Officer | Exercise or conversion | +34,570 | $3.12 | $108K | 79,100 |
| 2013-11-21 | Repella Robert SVP & Chief Commercial Officer | Sale | −64,100 | $12.12 | $777K | 15,000 |
| 2013-11-21 | Repella Robert SVP & Chief Commercial Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −23,040 | 166,445 | ||
| 2013-11-21 | Repella Robert SVP & Chief Commercial Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −34,570 | 21,680 | ||
| 2013-11-20 | Repella Robert SVP & Chief Commercial Officer | Exercise or conversion | +40,515 | $5.90 | $239K | 62,005 |
| 2013-11-20 | Repella Robert SVP & Chief Commercial Officer | Sale | −40,515 | $11.89 | $482K | 21,490 |
| 2013-11-20 | Repella Robert SVP & Chief Commercial Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −40,515 | 189,485 | ||
| 2013-11-19 | Repella Robert SVP & Chief Commercial Officer | Sale | −2,885 | $12.07 | $35K | 21,490 |
| 2013-11-19 | Polymeropoulos Mihael Hristos President and CEO | Sale | −8,928 | $12.07 | $108K | 471,636 |
| 2013-11-19 | Kelly James Patrick SVP, CFO, Sec & Treasurer | Sale | −3,348 | $12.07 | $40K | 28,816 |
| 2013-07-29 | Repella Robert SVP & Chief Commercial Officer | Exercise or conversion | +9,375 | 24,375 | ||
| 2013-07-29 | Repella Robert SVP & Chief Commercial Officer | Exercise or conversion · Restricted Stock Unit | −9,375 | 9,375 | ||
| 2013-07-29 | Polymeropoulos Mihael Hristos President and CEO | Exercise or conversion | +25,000 | 480,564 |
Page 33 of 36 · 717 trades